Translation Initiation Complex Antibody Sampler Kit #4763
Product Information
Kit Usage Information
Protocols
- 2013: Western Blotting
- 2067: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin)
- 2441: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence
- 2469: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 2490: Western Blotting
- 3469: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence
- 3591: Western Blotting
- 3592: Western Blotting
- 7074: Western Blotting
- 9741: Western Blotting
Product Description
Specificity / Sensitivity
Each antibody in the Translation Initiation Complex Antibody Sampler Kit detects endogenous levels of its target protein.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with a synthetic petide corresponding to residues surrounding Met316 of human eIF4A protein, Gly188 of human eIF4G, and the sequence of human eIF4E and human eIF4H. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to a sequence around Gly12 of human eIF4A1, residues at the amino terminus of human eIF4B, Ser422 of human eIF4B, Ser209 of human eIF4E, and Ser1108 of human eIF4GI. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.
Background
A variety of factors contribute to the important biological event of translation initiation. The Eukaryotic initiation Factor 4E (eIF4E) complex of translation initiation factors binds to the 5' m7 GTP cap to open up the mRNA secondary structure and allow small ribosome subunit binding (1). eIF4A, an eIF4 complex component that acts as an ATP-dependent RNA helicase, unwinds the secondary structure of the 5' mRNA untranslated region to mediate ribosome binding (2,3). EIF4E binds to the mRNA cap structure to mediate the initiation of translation (4,5). eIF4E interacts with eIF4G, a scaffold protein that promotes assembly of eIF4E and eIF4A into the eIF4F complex (5). eIF4B is thought to assist the eIF4F complex in translation initiation. eIF4H induces the RNA-dependent ATP hydrolysis catalyzed by the initiation factors eIF4A and eIF4B (2,6). eIF4H was further shown to determine the initial rate and extent of eIF4A-mediated mRNA secondary structure unwinding (7).
- Rogers, G.W. et al. (2001) J Biol Chem 276, 12598-608.
- Rogers, G.W. et al. (1999) J Biol Chem 274, 12236-44.
- Svitkin, Y.V. et al. (2001) RNA 7, 382-94.
- Sonenberg, N. et al. (1978) Proc Natl Acad Sci U S A 75, 4843-7.
- Gingras, A.C. et al. (1999) Annu Rev Biochem 68, 913-63.
- Richter-Cook, N.J. et al. (1998) J Biol Chem 273, 7579-87.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.